Summary

Vildagliptin, is a dipeptdyl peptidase 4 (DPP-4) inhibitor; DPP-4 is the enzyme that degrades glucagon-like peptide-1 (GLP-1). GLP-1 triggers glucose dependent insulin secretion, inhibits the secretion of glucagon, slows gastric emptying, and influences satiety. GLP-1 has a very short half-life, so by inhibiting the action of DPP-4, GLP-1 remains in its active form for a longer period. This article discusses updates on vildagliptin.

  • diabetes & endocrinology clinical trials
  • diabetes mellitus
View Full Text